GA
TGTX icon

GoalVest Advisory’s TG Therapeutics TGTX Stock Holding History

GoalVest Advisory’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,344
Closed -$31.4K – 432
2024
Q3 		$31.4K Buy
+1,344
New +$29.4K 0.01% 227
2022
Q3 		– Sell
-1,284
Closed -$7K – 306
2022
Q2 		$7K Buy
+1,284
New +$8.02K ﹤0.01% 261

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GoalVest Advisory's TGTX Position: Q4 2024 in Review

GoalVest Advisory sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 1,344 shares — an estimated $31.4K sold.

GoalVest Advisory first reported a position in TGTX in Q2 2022 and held it in 2 quarters. The position peaked at $31.4K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • GoalVest Advisory reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GoalVest Advisory sold 1,344 TG Therapeutics shares in Q4 2024, an estimated $31.4K.
  • GoalVest Advisory first reported a position in TG Therapeutics in Q2 2022 and held it in 2 quarters.
  • GoalVest Advisory's TG Therapeutics position peaked at $31.4K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on GoalVest Advisory's 13F filing for Q4 2024, filed 17 Jan 2025.